NCT00442364View on ClinicalTrials.gov

Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

August 31, 2009

Conditions
Varicose Veins
Interventions
DRUG

Polidocanol (1%) Microfoam (Varisolve)

Varisolve polidocanol 1% microfoam, maximum of 20ml injected into affected great saphenous vein.

PROCEDURE

Endovenous Microfoam Occlusion

Varisolve® polidocanol microfoam injection under duplex guidance to fill proximal and distal great saphenous vein and varicose tributaries.

Trial Locations (7)

15232

Pittsburgh

19107

Philadelphia

27157

Winston-Salem

27710

Durham

77030

Houston

90033

Los Angeles

98004

Bellevue

Sponsors
All Listed Sponsors
lead

Boston Scientific Corporation

INDUSTRY